The Food and Drug Administration has approved a device that uses electrical stimulation to reduce inflammation from rheumatoid arthritis.

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

Panelists discuss how bimekizumab’s dual IL-17A and IL-17F inhibition mechanism distinguishes it from other biologics and may provide effective treatment options for patients who have lost response to ...

Patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus frequently face anxiety and ...

Many people regard joint pain or stiffness as a natural phenomenon that occurs with age, but caution is needed because it may ...

Scientists from the University of Cambridge believe the breakthrough could 'improve the quality of life' for those suffering ...

ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flare-up, and ...

Cambridge University scientists have developed a material that can sense tiny changes within the body - such as during an ...

Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), ...

Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a cross-sectional physician-reported medical chart review and survey assessing patient ...